Clinical Trial

A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

Name: A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors — clinical trial record (NCT07288957)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ABSK131-101

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK131 in patients with MTAP-Deficient Advanced/Metastatic Solid Tumors to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.

Trial Details

NCT Number	NCT07288957
Lead Sponsor	Abbisko Therapeutics Co, Ltd
Conditions	Solid Tumors (Phase 1)
Enrollment	266 participants
Start Date	2025-07-22
Primary Completion	2028-12-30 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-17